Veterinary Answers Logo

Veterinary Answers Logo

Monday, June 30, 2008

More Consultants, More Species, More Specialties

Veterinary Answers is growing by leaps and bounds. We now have consultants to cover almost all the species and organ systems you will encounter in practice.

Jennifer S. Fryer, DVM - Internal Medicine

Courtney Baetge, DVM - Anesthesia

Georgina Barone, DVM, DACVIM - Neurology

Terri Bonenberger, DVM, DACVD - Dermatology

Natalie Carrillo, DVM, DACVIM - Large Animal Internal Medicine

Curtis W. Dewey, DVM, MS, Diplomate ACVIM (Neurology) and Diplomate ACVS

Joan Dzeizyc, DVM, DAVCO - Ophthalmology

Carol Gamble, DVM, Diplopmate ABVP - Avian

Michael Garvey, DVM, DACVIM - Small Animal Internal Medicine
DACVECC - Small Animal Critical Care

Chelsea Greenberg, DVM, MS - Oncology

John Hintermeister, DVM, Board Eligible ACVIM - Oncology

Eric Klaphake, DVM, Diplomate ACZS and Diplomate ABVP - Avian

Nicholas Millichamp, Bsc, PhD, DACVO - Ophthalmology

Christal Pollock, DVM, DAVBP - Avian

Jeffery P. Simmons, DVM, MS, DACVECC

Ian Spiegel, DVM, MPH, Diplomate ACVD

Thursday, June 26, 2008

RSS feeds for Veterinary Journals


Last year, during the food recall, it seemed like new foods were being added to the recall list on a daily basis and I had great difficulty keeping up. In fact, when my own cat had eaten recalled food, I did not find out until VetCentric called me at home and at the office to alert me. It was then that I discovered the FDA's RSS feed on recalls. Every day, I would check my RSS reader for the latest on recall alerts and I was no longer in the dark when new recalls were announced.

Since then, I have found RSS feeds to be a helpful way of keeping up with the latest veterinary literature. I read through the abstracts as soon as they are published online & then determine if I want to read the entire article. Many US veterinary college libraries allow veterinarians in their state to request individual articles for free or a reduced fee. You can also order individual articles through the Veterinary Information Network (VIN). The Royal College of Veterinary Surgeons subscribes to many veterinary journals and any veterinarian (whether in the UK or abroad) can become a member for a very reasonable price. This keeps printed journal subscriptions to a minimum and means less paper waste. And you can keep a pdf of each article on file in your computer, rather than paper files which take up so much space and time to maintain. You can also have a separate drive or an online service like Carbonite to back up your files, so that all your journal articles are still accessible if your computer is lost, stolen, destroyed, or self-destructs.

There are numerous RSS readers out there. I like Google Reader, as it is easy to read and is incorporated in to my Google account. Yahoo has a nice reader as well.

There are also services which will search newly released articles for parameters you set and either send you an email, or place it in a mailbox for you to check when you next login. PubMed's MyNCBI and Highwire both offer these services. On the human side, Amedeo will send you a weekly list of abstracts on the subject of your choice (from a menu) and journal of your choice (from a menu). I am trying to convince Amedeo to start a veterinary journal alert service. I will let you know if I am successful. Google recently added Google Alerts, which will send you email alerts when new entries for a specific search term come up. However, you cannot limit the search to journals - so lots of useless stuff may come up.

I have found lists of human medical journal RSS feeds, but have yet to find something similar in Veterinary Medicine. So here are the ones I have found so far. Please feel free to comment if you find additional links or have a problem with a link.

RSS FEEDS - Look for the orange symbols above to find the link for the RSS feed
American Journal of Animal and Veterinary Sciences
American Journal of Veterinary Research
Anatomia, Histologia, Embryologia: Journal of Veterinary Medicine
Australian Veterinary Journal
Brazilian Journal of Veterinary Research and Animal Science
Equine Veterinary Education
Equine Veterinary Journal
Journal of Small Animal Practice
Journal of the American Medical Association
Journal of the American Veterinary Medical Association
Journal of Veterinary Cardiology
Journal of Veterinary Emergency and Critical Care
Journal of Equine Veterinary Science
Journal of Veterinary Internal Medicine
Journal of Veterinary Pharmacology & Therapeutics
The Lancet
Medical and Veterinary Entomology
Mycoses
New England Journal of Medicine
New Zealand Veterinary Journal
Onderstepoort Journal of Veterinary Research (must scroll down list to find it)
Preventive Veterinary Medicine
Research in Veterinary Science
Topics in Companion Animal Medicine
Transboundary and Emerging Diseases
Tropical Animal Health and Production
Veterinary and Comparative Oncology
Veterinary Anaesthesia and Analgesia
Veterinary Dermatology
Veterinary Economics - free content
Veterinary Immunology and Immunopathology
The Veterinary Journal
Veterinary Medicine - free content
Veterinary Microbiology
Veterinary Ophthalmology
Veterinary Parasitology
Veterinary Pathology - free content
Veterinary Radiology and Ultrasound
Veterinary Research
Veterinary Research Communications
Veterinary Surgery
Zoonoses & Public Health


ELECTRONIC TABLE OF CONTENTS ALERTS, No RSS
Australian Equine Veterinarian
Indian Journal of Veterinary Pathology
Indian Journal of Veterinary Surgery
In Practice - British Veterinary Association
Journal of the American Animal Hospital Association
Journal of Animal Husbandry and Veterinary Medicine in Tropical Countries
Journal of Veterinary Behavior
Journal of Veterinary Diagnostic Investigation
Journal of Veterinary Medical Education
NAVC Clinician's Brief - Free registration & content
Veterinary and Comparative Orthopaedics and Traumatology
Veterinary Clinics of North America: Equine Practice
Veterinary Clinics of North America: Exotic Animal Practice
Veterinary Clinics of North America: Food Animal Practice
Veterinary Clinics of North America: Small Animal Practice
Veterinary Health and Safety Digest
The Veterinary Record


AVAILABLE CONTENT ONLINE IF YOU SUBSCRIBE, No RSS
Canadian Journal of Veterinary Research
Canadian Veterinary Journal
Compendium: Continuing Education for Veterinarians
Compendium Equine
Exotic DVM - free subscription for vets, techs, students
Flemish Veterinary Journal
Online Journal of Veterinary Research
The Pig Journal
Review of Medical and Veterinary Entomology
Review of Medical and Veterinary Mycology
Standards of Care
Veterinary Bulletin
Veterinary Clinical Pathology
Veterinary Focus - free subscription for vets, techs, students
Veterinary Forum
Veterinary Technician
Veterinary Therapeutics


FREE CONTENT, no RSS
British Veterinary Dental Association Journal
The International Journal of Applied Research in Veterinary Medicine
The Irish Veterinary Journal
Israel Journal of Veterinary Medicine
Japanese Journal of Veterinary Research
The Journal of Veterinary Medical Science (Japanese Society of Veterinary Science)
Journal of Veterinary Science
Turkish Journal of Veterinary and Animal Sciences
Veterinary Neurology and Neurosurgery
Veterinary Practice News
The Veterinary Quarterly
Veterinary Review
VetScite


OTHER INTERESTING LINKS
AVMA Directory - need AVMA membership
Canadian Compendium of Veterinary Products - need annual subscription
Compendium of Veterinary Products - need AVMA membership
FDA - News, Recalls, Drug shortages, etc.
Material Safety Data Sheets - need AVMA membership
Merck Veterinary Manual - Free Content
Veterinary Biologic Products - Licensees and Permittees -USDA- December 2007

Tuesday, April 29, 2008

EHV-1 the neuropathogenic strain

by Natalie Carrillo, MV, DVM, Dip ACVIM-LA

Recent outbreaks of myeloencephalopathy caused by equine herpesvirus (EHV-1) have generated new research that provides better information about diagnosis, treatment and outbreak management. The objective of this article is to summarize this information in a practical and applicable manner.

Clinical signs

The onset of EHV-1 myeloencephalopathy is characterized by a biphasic fever. In several outbreaks2 it has been observed that only horses younger than 5 years displayed fevers and respiratory signs, whereas the older horses were febrile, but had no signs of respiratory disease. It has also been observed that older horses develop neurologic deficits more frequently and of greater severity than younger horses (<5> 2. The reason for this bias is unknown, but may be explained by the role the horse’s immune system plays in the extent and severity of vasculitis and vascular thrombosis2.

The neurologic deficits appear approximately 4-6 days after the onset of fever2 and develop as the result of vasculitis, thrombosis and secondary ischemic degeneration of the neuropil1. The neurologic signs reflecting spinal cord involvement range from mild ataxia to recumbency, the pelvic limbs are more frequently involved and bladder atony is common. The brainstem may also be affected and therefore deficits of the cranial nerves may also be observed.

Epidemiology and outcome

The clinical signs are of rapid onset, but they also stabilize quickly. Most non recumbent animals do well, but the prognosis for recumbent horses is poor. In an outbreak of EHV-1 approximately 20-30 % of horses will be affected by the neuropathogenic strain, and of these the mortality will be approximately 30%1, 2.

Diagnosis

If you suspect a horse has EHV-1 due to an unexplained fever after being at an event, for example. A nasal swab and an EDTA purple top tube should be collected and submitted on ice packs overnight for real-time TaqMan® PCR on both samples to diagnose and differentiate the neuropathogenic vs non neuropathogenic strains. Results will be ready in 24h post arrival3. (See references for mailing addresses).

Outbreaks and treatment

In the event of a suspected outbreak there are guidelines on the AAEP website http://www.aaep.org/control_guidelines_nonmember.htm that pertain to biosecurity and quarantine. They are to extensive to cover, and are not the objective of this article. What I do want to incur into are treatment guidelines.

On the onset of fever of a suspected animal:

First implement biosecurity measures including stall confinement. Collect pertinent samples for diagnosis and then initiate therapy with NSAIDs such as flunixin meglumine 1.1 mg/kg or phenylbutazone 4.4mg/kg to manage the fevers.

Once the disease is confirmed or clinical signs of the disease progress to a working diagnosis of EHV-1, then more aggressive therapy and prophylaxis of surrounding animals should be initiated. All animals possibly exposed should be treated with Valacyclovir (Valtrex®) 205-403 mg/kg PO every 8 hours. Acyclovir despite clinical reports of effectivity2 has shown not to reach adequate serum levels to inhibit viral replication6 therefore should not be the first drug of choice. Valtrex® is an expensive drug and this option should be thoroughly discussed with the owner.

Management for the horses displaying clinical signs of the neuropathogenic form of EHV-1:

NSAIDs - continue flunixin meglumine 1.1mg/kg for 10 d (monitor serum creatinine every 3-5d depending on hydration status of the horse).

DMSO (if you are a believer) 1g/kg at 20% sol IV every 24h for 3 days, as a free radical scavenger.

Valacyclovir (Valtrex®) 205-403 mg/kg PO every 8 hours for 10 days or until clinical signs stabilize.

Vitamin E 10.000 IU PO every 24h for 10 days7 as an antioxidant.

Dexamethasone 0.1 mg/kg IV for 3 days then taper for a total of 10d. This therapy is controversial. On one hand it is a potent anti-inflammatory, but on the other it does suppress the immune system at these doses. And never forget the potential for laminitis. I would reserve this choice of therapy for horses showing neurological deficits, I would not administer to horses with just a fever, even if it is a confirmed case.

If at any point a horse should become recumbent or needs assistance standing, or in general deteriorates to the point of requiring constant monitoring please talk to the client about referral to a hospital with facilities for critical care.

Vaccination in an outbreak

From http://www.vetmed.ucdavis.edu/ceh/topics-EHV-1-vaccinations.htm

On premises with confirmed clinical EHV-1 infection, booster vaccination of horses likely to be exposed is not recommended.

Non-exposed horses or horses that have to enter the premises should have a booster vaccination if they have not been vaccinated within the past 90 days. This does not guarantee protection against the disease; the hope is that reduced nasal shedding of infectious EHV-1 by these horses will help reduce the magnitude of challenge experienced by other horses and potentially help reduce spread.

A current publication8 showed that recent vaccination with Rhinomune (modified live vaccine) may provide some protection against EHV-1 myeloencephalopathy. These results should be interpreted with caution because the number of animals used in the study was small.

Vaccines that provide the highest levels of viral neutralizing titers are Pneumabort, Prodigy, Calvenza and Rhinomune. The high levels of antibodies have been shown to reduce viral shedding. It is important to warn clients of the potential side effects of the modified live vaccine such as swelling of the injection site, fever and swelling of the limbs.

I hope this article has been helpful, if you should have any further questions about a case please do not hesitate to contact me.

References:

1.- Julia H. Kydd and K.C. Smith, Equine Herpesvirus Neurologic Disease: Reflections from across the pond. J Vet Intern Med. 2006 May-June;20(3):467-68.

2.- Henninger RW, et al, Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J Vet Intern Med. 2007 Jan-Feb;21(1):157-65.

3.- Allen GP, Development of a real-time polymerase chain reaction assay for rapid diagnosis of neuropathogenic strains of equine herpesvirus-1.J Vet Diagn Invest. 2007 Jan;19(1):69-72. M.H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY 40546.

4.- Garré B, et al, Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug Valacyclovir in healthy adult horses. Antimicrob Agents Chemother. 2007 Dec;51(12):4308-14. Epub 2007 Sep 10.

5.- BG Bentz, et al, Pharmacokinetics of Valacyclovir in the adult horse. Abstract #108 J Vet Intern Med. 2007 May-June;21(3):601.

6.- BG Bentz et al, Pharmacokinetics of Acyclovir after Single Intravenous and Oral Administration to Adult Horses. J Vet Intern Med. 2006 May-June;20(3):467-68.

7.- J.K. Higgins, et al, Vitamin E levels in serum and cerebrospinal fluid of healthy horses following oral supplementation. Abstract #340 J Vet Intern Med. 2007 May-June;21(3):666.

8.- Goodman LB, et al, Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).

Vaccine. 2006 Apr 24;24(17):3636-45. Epub 2006 Feb 13.

Emergency Management of the Blocked Ferret

By Christal Pollock, DVM, DABVP-Avian

Diagnosis of urethral obstruction in the male ferret is rarely a diagnostic challenge, but the need to place a urinary catheter in a 1-kg patient can be intimidating.

Urinary catheter placement can be challenging in the male ferret because of its small size and its J-shaped os penis. Locate the prepuce on the ventral abdomen just caudal to the umbilicus. The os penis is palpable. After gently extruding the penis, it may help to grasp the base with a gauze square. Aseptically prepare the penis, and use a 24-gauge catheter with the needle removed to find and dilate the urethral opening. The urethral opening is located on the ventral surface of the penis just proximal to the J-shaped curve.

After the urethral opening is found and dilated, pass a urinary catheter. A 3.5 Fr red rubber catheter may be used in a very large male, however most individuals require a smaller tube. A 3-Fr 11-in urinary catheter specifically designed for ferrets is available (Slippery Sam, Global Veterinary Products; New Buffalo, MI) or a 22- or 20-gague jugular catheter may be used. Pre-measure red rubber catheters and jugular catheters. Leave the jugular catheter stylet in place to facilitate passage, but manipulate the catheter carefully. Resistance most often occurs as the catheter travels around the pelvic flexure. Gently flush the urethra with sterile saline to facilitate catheter passage.

· Anesthesia is required for adequate muscle relaxation. Most individuals should be intubated and maintained on isoflurane or sevoflurane when anesthetized for extended periods. Avoid ketamine in ferrets with urethral obstruction.

· When urinary catheterization proves difficult, remove a small amount of urine once via cystocentesis to reduce pressure and allow passage of the urinary catheter. Repeated cystocentesis is not recommended because of thin bladder wall. In rare cases, percutaneous cystostomy may be performed when catheter placement fails.

· Suture butterfly tape strips near the prepuce to secure the catheter. Use tape to fasten the catheter or attached tubing to the tail base to minimize tension on the line. Bandaging the abdomen may also minimize the risk of rotation. Create a closed collection system by attaching a small intravenous bag and monitor urine production. The average 1-kg ferret produces 26-28 ml of urine over a 24-hour period (range: 8-48 ml).

· To catheterize the female ferret, place her in ventral recumbency and elevate the rear with a rolled towel. Aseptically prepare the vulva and perivulvar region, and then insert a sterile vaginal speculum or otoscope. Locate the urethral opening on the vestibule floor 1-cm cranial to the clitoral fossa. Insert a 3.5-Fr red rubber catheter, which may be fitted with a wire stylet.

The most important cause of dysuria or stranguria in the male ferret is prostatomegaly secondary to adrenal disease. Struvite urolithiasis may also cause urethral obstruction, however the incidence is relatively low now that ferret food is commercially available. (Cystitis and prostatic abscesses are uncommon but potential causes of stranguria and dysuria in the ferret). History and physical examination may provide clues to the underlying cause of urethral obstruction, but signalment is not particularly helpful. Most affected ferrets are middle aged to older, although any age may be affected.


Adrenal disease

Struvite urolithiasis

Diet

Good diet (Animal protein-based)

Bad diet (Plant protein-based)

Exam findings

Dorsal symmetrical alopecia

—–

Laboratory results

+/- Urinary tract infection

Non-regenerative anemia

Urinary tract infection

Crystalluria

Radiographs

Unremarkable

Radiopacity

Ultrasonography

Prostatomegaly

Adrenomegaly

—–

· Ferret adrenal disease is associated with an elevation in sex steroid hormones, and elevated androgen levels can leads to prostatomegaly. Dorsal symmetrical alopecia is also a common clinical sign.

· Ferrets require high quality, animal-based dietary protein. Therefore a low quality, plant protein-based diet promotes development of alkaline urine and struvite crystalluria.

· Ferrets normally have relaxed abdomens that are easy to palpate. Although pain will cause the abdominal muscles to tense, the over distended bladder is still palpable. There may also be evidence of urine dribbling and the prepuce may be red from excessive licking.

· Normal ferret biochemistry is similar to that in other mammals with a few exceptions. Creatinine in the ferret generally ranges from 0.1-0.3 mg/dL with values almost always less than 0.5 mg/dL. Creatinine from 0.7-1.0 mg/dL signifies azotemia.

· Obtain whole body survey radiographs using tabletop technique, high-speed film, and fine screen cassettes. Contrast radiography may be useful in identifying urethral stones. Enlarged adrenal glands are rarely visible on radiographs, and ultrasonography is needed. Note that renal cysts are a common incidental finding.

· Ferrets are relatively stoic animals, but do not ignore pain management. Provide preemptive analgesia, and monitor ferrets carefully for signs of discomfort. Signs of pain may include anorexia, lethargy, crying, stiff movements, squinting, and an inability to sleep in a natural, curled position.

References & Further Reading

Castanheira de Matos RE, Morrisey JK. Common procedures in the pet ferret. Vet Clin North Am Exot Anim Pract 2006; 9: 347-365.

Esteves MI, Marini RP, Ryden EB, et al. Estimation of glomerular filtration rate and evaluation of renal function in ferrets (Mustela putorius furo). Am J Vet Res 1994;55:166-172.

Pollock CG. Emergency medicine of the ferret. Veterinary Clinics of North America: Exotic Animal Practice. 10(2): 463-500, 2007.

Quesenberry KE, Carpenter JW, eds. Ferrets, rabbits, and rodents: clinical medicine and surgery. 2nd ed. St. Louis: WB Saunders Co, 2003: 2-134.

More Consultants

Anesthesia

Courtney S. Baetge, DVM – Board Eligible in Anesthesia


Dermatology

Terri Bonenberger, DVM, DACVD


Emergency / Critical Care

Michael S. Garvey, DVM, DACVIM (SA-IM), DACVECC

Megan Ridley, DVM


Exotics/Avian

Christal Pollock, DVM, DABVP-Avian


Large Animal Internal Medicine

Natalie Carrillo, DVM, DACVIM (LA-IM)


Oncology

Chelsea Greenberg, DVM, DACVIM (Oncology)

John Hintermeister, DVM, Board Eligible in Oncology


Ophthalmology

Joan Dziezyc, DVM, DACVO

Nicholas Millichamp, Bsc, PhD, DACVO


Neurology

Georgina Barone, DVM, DACVIM (Neurology)


Radiology

Pet Rays 1-888-4-PETRAYS or www.petrays.com


Small Animal Internal Medicine

Jennifer S. Fryer, DVM – Board Eligible in Internal Medicine

Michael S. Garvey, DVM, DACVIM (SA-IM), DACVECC

Wednesday, March 12, 2008

Disorders of the Brain Part I: Update on current trends, diagnostic tools, and treatments of congenital encephalopathies

By Georgina Barone, DVM, DACVIM (Neurology)

Canine congenital encephalopathies comprise a broad range of developmental disorders. Clinical signs are dependent upon the area of the brain affected and may indicate whether the patient has focal, multifocal, or diffuse disease. A thorough neurologic examination is essential to determine neuroanatomic localization and make appropriate diagnostic and treatment recommendations. It is also imperative that other diseases that may contribute to neurologic deficits be ruled out such as hypoglycemia, porto-systemic shunts, infectious diseases, and inborn errors of metabolism. When evaluating a dog with a suspected intra-cranial developmental anomaly, the veterinarian should consider the following factors. First, is the abnormality of clinical significance? Some anomalies do not produce clinical signs and must be interpreted in light of the patient’s condition. Second, the animal must be evaluated for other malformations. Embryologic development of the brain is closely related to that of the spine and other tissues. Critical evaluation of all organ systems is essential to determine the viability of the dog as a pet. Heritability of the problem is also of key importance to the breeder, although many anomalies occur as sporadic occurrences. Lastly, treatment options and quality of life concerns must be addressed as many anomalous conditions of the CNS carry a guarded to poor prognosis with them.

This article will provide information on some of the more common congenital anomalies seen in our canine patients. Acquired disorders will be addressed in a future newsletter.

Quadrigeminal cysts (QC) are widely believed to be developmental anomalies that arise in close proximity to an intra-cranial arachnoid cistern, most commonly the quadrigeminal cistern located above the cerebellum. They represent accumulation of cerebrospinal fluid between sheets of the arachnoid layer of the meninges and lack an epithelial lining, thus are considered “pseudo-cysts”. Once thought to be rare, these anomalies are increasingly being recognized, most likely due to the greater availability of advanced imaging such as CT and MRI.

Small-breed dogs, particularly brachycephalic breeds (especially Shih-tzu’s) and male dogs are over-represented. Although clinical signs can be variable, one of the most common signs are generalized seizures, likely due to the pressure on the occipital lobes of the cerebrum by pressure from the cystic mass. Additionally, ataxia, intention tremors, paresis, and head tilt have all been reported. Support for the developmental nature of this disease stems from the fact that most patients are young (<1> Occasionally, QC’s are found as incidental findings, either on necropsy or brain imaging.

fig-1-crop.jpg Figure 1 – Arachnoid Cyst

fig-2-crop.jpg Figure 2 – Arachnoid Cyst

Diagnosis of arachnoid cysts requires advanced imaging, preferably MRI or 3-D CT scanning. MRI (see Figures 1 & 2) will reveal a mass lesion rostro-dorsal to the cerebellum and caudal to the occipital lobes. The lesion appears hyper-intense on T2 images and hypointense on T1 images and is non-contrast enhancing. The quality of the lesion is virtually indistinguishable from cerebrospinal fluid. Variable degrees of compression and distortion of the adjacent cerebellum and cerebrum can be observed. Concurrent hydrocephalus has been reported, but this is likely a breed-related variant of ventricle size and unlikely to be of clinical significance. QC must be differentiated from cystic neoplasia or cysts associated with infectious disease (e.g. hydatid cyst).

Treatment of QC’s include surgery (fenestration, shunting, or marsupialization) or medical management (e.g. corticosteroids and carbonic anhydrase inhibitors), but controversy still remains over the preferred treatment. Prognosis must be considered guarded and the majority of dogs require life-long anticonvulsant therapy, even if surgical correction is performed.

Hydrocephalus refers to an increased volume of cerebrospinal fluid within the ventricular system and is most commonly recognized within the first few months of a dog’s life. The pathophysiology of congenital hydrocephalus is complex and mutifactorial but may be associated with fusion of the rostral colliculi, pre-natal infections causing stenosis of the mesencephalic aqueduct, compromise of cerebral vasculature, and intrauterine toxicity. Breeds at risk include Chihuahua’s, Yorkshire Terrier’s, Poodle’s, and a variety of brachycephalic breeds. Clinical signs generally are apparent prior to 6 months of age and are highly variable but usually include evidence of a prosencephalic disturbance. Abnormal mentation, visual deficits, circling, poor response to training, head pressing, seizures, and pacing have all been reported. Occasionally, hindbrain signs will predominate with ataxia, head tilt, abnormal nystagmus, and balance loss. Physical examination may reveal a large, dome-shaped head (Figure 3), calvarial defects, or an open fontanelle. Bilateral ventrolateral strabismus (“sunset eyes”) is seen as a sequelae to the skull malformation rather than as an indication of a vestibular disturbance.

figure-32-3.jpg

Figure 3 – Dome-shaped head in Hydrocephalus

Diagnosis is generally straightforward and is based on signalment, clinical signs, physical exam findings, and confirmation of ventriculomegaly. It must be understood that enlargement of the ventricles and the presence of an open fontanelle are not necessarily of any clinical significance. The patient must demonstrate signs of a brain disorder in the absence of any concurrent, active causal disease that may be responsible (e.g. encephalitis, metabolic encephalopathy). In patients with a patent fontanelle, the diagnosis may be confirmed with ultrasonography. Advanced imaging (CT, MRI) is the preferred method for imaging and confirming the diagnosis and for ruling out any concurrent disorders. MRI (Figure 4) will reveal dilation in the ventricular system and loss of the adjacent parenchyma.

fig-4-crop.jpg

Figure 4 – Hydrocephalus MRI

Treatment is aimed at reducing CSF volume and production. Prednisone or carbonic anhydrase inhibitors have been used with variable success. Surgical intervention is the treatment of choice and is aimed to divert CSF away from the ventricular system to the peritoneal cavity, pleural space, or right atrium. Ventriculoperitoneal shunting is the most common, technically feasible procedure done in domestic animals and can be done even on very small patients, such a Chihuahua’s. Prognosis is highly variable and depends on the degree of pre-operative neurologic dysfunction, chronicity, and avoidance of complications (infection, occlusion) associated with the shunt. Success rates as high as 90% have been reported with ventriculoperitoneal shunts, but owners must be advised that long-term prognosis for full return to function is guarded.

Chiari-Like Malformation (Caudal Occipital Malformation Syndrome or “COMS”) is a developmental anomaly that is being increasingly recognized as advances in neuroradiology are made. Anatomic abnormalities of the skull, specifically the occiput, result in compression of the structures of the caudal fossa and lead to cerebellar herniation. Consequently, there is alteration in the dynamics of cerebrospinal fluid flow and pressure on the cranial aspects of the spinal cord. Pressure gradients resulting from altered CSF flow as well as constriction of the cervicomeduulary junction at the foramen magnum result in the development of excessive fluid buildup within the spinal cord, either confined to the central canal (hydromyelia) or within the neuroparenchyma (syringomyelia). Collectively, the condition is referred to as syringohydromyelia (SM).

COMS is most often diagnosed in small breed dogs, especially Cavalier King Charles Spaniels. Other breeds being seen with increasing regularity include the Pomeranian, Pug, and other brachycephalic breeds. Affected animals can display a wide array of clinical signs including cerebellovestibular dysfunction, seizure activity, cervical/cranial hyperesthesia, or persistent scratching at the neck and shoulder region. Although it is considered to be a developmental disorder (most are diagnosed by 3 years), age at diagnosis can vary and clinical signs may not be evident until the animal is several years old. This is likely due to the fact that syringomyelia may take years to develop; the author has observed dogs that did not begin to display clinical signs until 7 or 8 years of age.

fig-5-crop.jpg Figure 5 - MRI of COMS & SM

fig-6-crop.jpg Figure 6 – MRI of COMS & SM

MRI is considered to be the diagnostic tool of choice to confirm COMS and SM (Figures 5 & 6). MRI findings in this condition include rostral displacement of the cerebellum by the occiput, obliteration of the dorsal subarachnoid space at the cervicomedullary junction, and cervical syringohydromyelia. Ventriculomegaly can also be observed but may be a normal variant in brachycephalic breeds and must be interpreted with caution. Additional diagnostics are currently being evaluated by researchers and include spiral CT scanning and brain-stem auditory evoked responses (BAER).

Medical management is directed toward relieving pain and decreasing CSF production. Commonly prescribed drugs include corticosteroids, narcotics, gabapentin, pregabalin, and carbonic anhydrase inhibitors. While medical therapy may effectively alleviate discomfort, long term prognosis is poor if the underlying anomaly is not addressed and treated. Progression of SM leads to pressure on the spinal cord parenchyma leading to permanent nerve damage and eventually intractable pain and paralysis. The treatment of choice in humans with COMS is Foramen Magnum Decompression (FMD) and the majority of human patients that undergo FMD either experience a halt in the progression or improvement in clinical signs. There is increasing evidence that FMD is the preferred method of treatment in dogs as well. Without surgery, more than 1/3 of dogs will be euthanized due to chronic severe pain and quality of life concerns. FMD allows for removal of hyperplastic occipital bone and relieves pressure on the underlying parenchyma. Often, SM will resolve or improve after the procedure, as evidenced by serial MRI exams. Unfortunately, in humans and animals, recurrence rate is high due to formation of scar tissue at the previous surgical site which in essence, recreates the original defect. A modification of the FMD in which titanium is placed over the defect created by the FMD to prevent excessive scar tissue has shown great promise with significantly fewer animals requiring re-operative procedures.

Other brain anomalies: Many other anomalies of the brain have been reported sporadically in dogs and should be considered when evaluating a pediatric patient with intracranial signs. Hydranencephaly has been reported in Labrador Retriever puppies and results from in utero destruction of previously viable neocortex during a critical period of development. Unlike hydrocephalus, the cranial cavity is of normal configuration. Imaging findings are similar to those seen with hydrocephalus but prognosis is extremely guarded. Lissencephaly (Figure 7) occurs when the normal cerebrocortical folds fail to develop, leading to an absence of gyri and sulci of the cerebral hemispheres. Lhasa Apso’s are most commonly affected, but the disease has also been reported in Irish Setters and Wire Hair Fox Terriers. Clinical signs include aggression, blindness, poor training ability, and generalized seizures. Seizures often do not occur until the animal is greater than 1 year of age and tend to be refractory to standard anticonvulsants. Prognosis is grave. Other defects in neuroparenchymal development (Figure 8 ) are seen infrequently and are poorly understood.

fig-7-crop.jpg Figure 7 – Lissencephaly

fig-8-crop.jpg Figure 8 – Defect in neuroparenchymal development

PetRays Affiliation

Veterinary Answers is now partnering with PetRays to provide our clients with rapid access to quality radiology consultations with a 4 hour turnaround on routine requests and 30 minutes on STAT requests. Soon, all Veterinary Answers consultants will be available at the click of button via your PetRays account software. This will speed up our turnaround on consults and provide you with an archive of both your radiology and medicine reports.

Call 1-888-4PetRays to set up an account to start receiving rapid radiology consults.

Monday, January 21, 2008

Veterinary Answers Adds New Consultants

Georgina Barone, DVM, DACVIM (Neurology)

Terri Bonenberger, DVM, DACVD (Dermatology)

Michael Garvey, DVM, DACVIM (Internal Medicine), DACVECC (Critical Care)

Call us with your questions. We’re here to help.

Wednesday, January 2, 2008

Calcitriol?

By Jennifer S. Fryer, DVM

One of the most common diseases we treat as small animal veterinarians is renal failure and renal insufficiency in cats and dogs. We are desperate to do more for these patients – to keep them eating and comfortable with minimal intervention for as long as possible. In the past 10 years, there has been much controversy regarding the use of calcitriol (1,25 dihydroxyvitamin D) to slow the progression of renal failure in cats and dogs.

In lab animal research and years of human use, calcitriol has been used to reduce renal secondary hyperparathyroidism. However, evidence suggests that it is most effective before the onset of excess parathyroid hormone secretion and the hyperphosphatemia that results. Newer synthetic vitamin D analogs may have other actions besides vitamin D receptor activation that benefit ill kidneys, although their injectable, short-acting formulations limit their use in veterinary medicine. A recent study of calcitriol use in cats showed no decrease in PTH concentrations in either normal or renal failure cats. This suggests that if the goal is to reduce PTH, the doses used in this study were not adequate, the sample size was too small, or the trial length too short.

The key question for veterinarians and clients, is whether the use of calcitriol will benefit an individual patient. While mulling over this question, the motto “DO NO HARM” lurks inevitably in the foreground. I have seen many patients, particularly cats, who lived far long and better on calcitriol than expected. Although the same can be said of some animals with renal failure NOT on calcitriol, especially those on a phosphorus-restricted renal diet.

What are the risks?

· Animals can become hypercalcemic at any time during therapy (days, weeks, months, years). Since this cannot be predicted, frequent blood calcium & phosphorus monitoring is essential. Once detected, stopping calcitriol and later reducing the dose typically resolves the hypercalcemia. However, if the animal has had a Ca x P > 60 for a prolonged period this may result in permanent dystrophic mineralization and reduced GFR.

· Dystrophic mineralization is also a risk for patients who are hyperphosphatemic.

What are the benefits?

· Delayed onset of renal secondary hyperparathyroidism and signs of uremia.

· Improved quality of life.

Which animal is a candidate?

· Renal failure or insufficiency with normal total and ionized calcium and phosphorus <>

· The animal must have an owner willing to commit to the time and expense of frequent monitoring – q 1 week initially, then q 1-2 months for the duration of Calcitriol therapy.

o I typically Rx only 1 month’s worth of calcitriol at a time. I put no refills on the 1st Rx and only 1 refill on subsequent Rx’s to encourage the owner to return for recheck blood work. No refills will be given until the patient returns.

o Warn owners of the potential for hypercalcemia and worsening of renal disease, even despite close monitoring.

Monitoring

· Obtain baseline chemistry panel (must include total calcium, phosphorus, BUN, creatinine) and baseline PTH and ionized calcium.

· Start calcitriol at the low end of the dose if PTH is elevated. Recheck calcium, phosphorus, BUN, creatinine in 1 week. If values are stable, continue for 3 more weeks.

· At 1 month, repeat chemistry panel (must include total calcium, phosphorus, BUN, creatinine) and baseline PTH and ionized calcium.

· If PTH is within normal limits, continue at the same dose of calcitriol and recheck q 1-2 months. If PTH remains above normal limits, increase the dose (up to 3.5 ng/kg/day) and recheck in 1 week and in 4 weeks.

· If hypercalcemia occurs, stop calcitriol and recheck total calcium, phosphorus, BUN, creatinine in 1 week. If the hypercalcemia has resolved and phosphorus remains below 6 mg/dl, consider restarting calcitriol at 50% the previous dose. Others discontinue calcitriol altogether at this point.


Tuesday, December 18, 2007

The World of Epidurals

By Courtney L. Baetge, DVM

If I have learned anything during my time as an anesthesiologist, it is that for every topic there are a multitude of opinions. But I do believe most anesthesiologists are strong advocates of epidurals. The benefits of an improved anesthetic plane, smoother recovery and superior post-operative pain control well outweigh the additional time and effort involved in placing an epidural. However, for those who don’t do epidurals on a regular basis, they can seem a bit intimidating. I feel the skill is a small portion of this intimidation. Most practitioners with just a little practice become adept quite quickly. Most of our fourth year veterinary students can perfect the skill during the 2 week rotation. Having said this, why are they so scary? There are a lot of “other things” involved with an epidural than just the technique. Knowing when, where, who, and what are just a few. So let’s try and address a few of these (and how).

When
Most patients that will have a painful procedure done anywhere caudal to the umbilicus will appreciate an epidural. Obvious ones are rear limb surgeries and perineal hernias. But the less obvious cases include exploratory laparotomies, mastectomies, anal sac carcinomas, and preputial surgeries, just to name a few.

Where
The subarachnoid space stops at L7 (can go further in young or very small dogs). So attempting epidurals at L7-S1, helps decrease the chance of causing damage to the spinal cord and performing a spinal rather than an epidural. However, if you end up getting CSF coming out of your needle simple reduce your dose by half and keep going. This will speed your onset of action but decrease your duration as well. There are times when the pelvis anatomy is not ideal and going to the L6-L7 space is easier. That’s fine!

Who
More importantly is who NOT to give epidurals. Do not use an epidural if there is infection at the injection site, the patient is hypovolemic, the patient has a bleeding disorder or is on anticoagulants, axonal disease, severe anatomical abnormalities, or neurologic disorders. You do not want to spread any infections into or out of the spinal canal.

What
If there is a drug created, some researcher has tried putting it in some poor animal’s epidural space. BUT, there are a few drugs that most anesthesiologists consider staples. The drugs should be preservative free (the preservative in typical morphine is formaldehyde). The total volume should be less than 0.2 ml/kg [if the patient is very obese or pregnant the space will be smaller due to venous congestion and the dose should be reduced (0.15ml/kg)]. I tend to max out at 6 ml, especially if using a local, so there is less risk of respiratory or sympathetic blockade.

Opioids: Morphine [0.1 mg/kg] has a nice long duration of analgesia (12-24 hrs) without motor blockade or sympathetic nervous system blockade and will migrate well cranially to increase your area of analgesia. However, it can take up to 1 hr to begin working and can cause respiratory depression, urinary retention, decreased GI motility, vomiting and itching. Fentanyl is another opioid that can be used. It has a duration of 2-6 hrs, with a smaller area of analgesia and less systemic effects.

Local anesthetics: Lidocaine has a fast onset of action (10-15 minutes) but will only last about 60-120 minutes. Lidocaine can also cause respiratory depression and sympathetic nervous system blockade that can lead to hypotension. Bupivicaine has a longer onset of action (20-30 minutes) and a longer duration of action (4-6 hours).

Combining a local and opiod can give you the best of both worlds. I usually just reduce by opioid volume by 25% and replace that with local anesthetic. For instance, in a 10 kg dog at 0.1 mg/kg of morphine, you would use 1 mg of morphine which, if the 0.5 mg/ml Duramorph is used, equals 2 ml of morphine. Therefore, I would reduce my dose to 1.5 ml of morphine and add 0.5 ml of a preservative-free local anesthetic like bupivicaine for a total of 2 mL.

How
It is usually helpful for most people to have the patient in sternal recumbency with the rear legs pulled as far cranially as possible. This opens the L7-S1 space up and gives a larger target for your needle. The area is clipped and sterilely prepped. The thumb and middle finger rest on the wings of the pelvis which should direct the first finger to fall into the L7-S1 space directly between the thumb and middle finger. I tend to use a 20-22g 2 ½ to 3 ½ inch epidural needle, depending on the size and amount of fat at the injection site. An epidural needle is always preferred since the bevel is not a cutting edge and is less likely to damage the spinal cord if accidentally nicked. I turn the bevel to which ever direction needs the greatest analgesia (i.e. caudally for hernia repair, left for left stifle surgery, cranial for mastectomy). Once past the skin and majority of the fat, I remove the stylet and attach a test syringe of sterile saline or place a “hanging drop” so that I can see when I get negative pressure. The negative pressure may be gone in some patients but a test injection of saline should flow very easily (like an IV injection). Once in place, I inject my drug. If you get blood, stop and pull the needle out – it’s not the day for an epidural.

Hopefully this will help anyone trying to ease into the epidural world. Practice, be sterile, and good luck!